Clinical Trial Assesses First-of-its-Kind, One-Time Medical Procedure in Patients with Severe Asthma Minneapolis, Minn., March 27, 2018 – Nuvaira, a developer of medical devices to treat obstructive lung diseases, today announced treatment of the first patient in the RELIEF-1 Clinical Study in Europe. The RELIEF-1 trial (NCT02872298) is a prospective, multi-center, single-arm (non-randomized) study designed to evaluate the safety and technical feasibility of a procedure called Targeted Lung Denervation (TLD) using the Nuvaira™ Lung Denervation System for the treatment of severe asthma. The feasibility study is slated to treat a total of 30 patients at facilities in France, Germany, the […]
3750 Annapolis Lane North
Minneapolis, MN 55447
© 2018 Nuvaira Inc. All rights reserved.